Ashrafi Jigheh Zahra, Ghorbani Haghjo Amir, Argani Hassan, Roshangar Leila, Rashtchizadeh Nadereh, Sanajou Davoud, Nazari Soltan Ahmad Saeed, Rashedi Jalil, Dastmalchi Siavoush, Mesgari Abbasi Mehran
1Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
2Student Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Indian J Clin Biochem. 2020 Jan;35(1):109-114. doi: 10.1007/s12291-018-0790-6. Epub 2018 Sep 17.
Empagliflozin, a SGLT-2 inhibitor, improves diabetic nephropathy through its pleiotropic anti-inflammatory effects. The present study aims to evaluate empagliflozin effects on renal and urinary levels of tubular epithelial cell injury markers in streptozotocin-induced diabetic rats. Empagliflozin at 10 mg/kg (p.o.) was administered for 4 weeks, beginning 8 weeks after induction of diabetes. Renal function as well as markers of renal tubular epithelial cell injury were assessed in kidney tissue homogenates and urine. Empagliflozin was able to ameliorate diabetes induced elevations in serum cystatin C levels. It also alleviated renal KIM-1/NGAL levels and urinary albumin, α-GST, and RBP excretions. In addition to decreasing urinary levels of cell cycle arrest indices i.e. TIMP-2 and IGFBP7, empagliflozin mitigated acetylated NF-κB levels in renal tissues of diabetic rats. As a whole, these findings reveal empagliflozin capability in improving diabetic nephropathy via ameliorating indices of renal inflammation, injury, and cell cycle arrest on streptozotocin-induced diabetic rats.
恩格列净是一种钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂，通过其多效抗炎作用改善糖尿病肾病。本研究旨在评估恩格列净对链脲佐菌素诱导的糖尿病大鼠肾脏和尿液中肾小管上皮细胞损伤标志物水平的影响。从糖尿病诱导8周后开始，以10mg/kg（口服）的剂量给予恩格列净，持续4周。在肾脏组织匀浆和尿液中评估肾功能以及肾小管上皮细胞损伤标志物。恩格列净能够改善糖尿病引起的血清胱抑素C水平升高。它还减轻了肾脏KIM-1/中性粒细胞明胶酶相关脂质运载蛋白（NGAL）水平以及尿白蛋白、α-谷胱甘肽S-转移酶（α-GST）和视黄醇结合蛋白（RBP）的排泄。除了降低细胞周期停滞指数即金属蛋白酶组织抑制因子-2（TIMP-2）和胰岛素样生长因子结合蛋白7（IGFBP7）的尿液水平外，恩格列净还减轻了糖尿病大鼠肾组织中乙酰化核因子κB（NF-κB）的水平。总体而言，这些发现揭示了恩格列净在改善链脲佐菌素诱导的糖尿病大鼠的糖尿病肾病方面具有通过改善肾脏炎症、损伤和细胞周期停滞指标的能力。
